Who is sponsoring NCT03911219?

NCT03911219 is sponsored by iOMEDICO AG.

What drugs are being tested in NCT03911219?

Interventions in NCT03911219: eHealth system support for symptom management via CANKADO.

What condition does NCT03911219 study?

NCT03911219 studies Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer, Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC.

Is NCT03911219 still recruiting?

NCT03911219 is currently completed. Last updated 5 October 2021.

Last reviewed 2021-10-05 · How we verify

NCT03911219: CHAPLIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

Completed Last updated 5 October 2021

What this trial tests

trial testing eHealth system support for symptom management via CANKADO in Stage IV Non-small Cell Lung Cancer in 154 participants. Completed in 1 July 2021.

Timeline

10 July 2019

Primary endpoint
1 July 2021

1 July 2021

Quick facts

Lead sponsor	iOMEDICO AG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	154
Start date	10 July 2019
Primary completion	1 July 2021
Estimated completion	1 July 2021
Sites	92 locations across Germany

Drugs / interventions tested

eHealth system support for symptom management via CANKADO

Conditions studied

Stage IV Non-small Cell Lung Cancer — all drugs for Stage IV Non-small Cell Lung Cancer →
Extensive-stage Small Cell Lung Cancer — all drugs for Extensive-stage Small Cell Lung Cancer →
Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC — all drugs for Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC →

Sponsor

iOMEDICO AG — full company profile →

Who can join

18 and older, any sex, with Stage IV Non-small Cell Lung Cancer or Extensive-stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study is aimed to test the benefit of a web-based application tool in NSCLC, SCLC and TNBC patients during the recently approved first-line treatment strategy with atezolizumab in combination with chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives.
Aapro M, Bossi P, Dasari A, Fallowfield L, et al · · 2020 · cited 195× · PMID 32533435 · DOI 10.1007/s00520-020-05539-1

Verify or expand the search:

Other recruiting trials for Stage IV Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
NCT06167460 — Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. · recruiting
NCT04900935 — Patient-centered, Optimal Integration of Survivorship and Palliative Care · NA · recruiting
NCT04056247 — Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments · active not recruiting
NCT03742687 — Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC · NA · recruiting

Other iOMEDICO AG trials

Trials by the same sponsor.

NCT06619275 — Ripretinib (QINLOCK®) According to Current SmPC · completed
NCT06181734 — Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC · completed
NCT05954780 — Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma · active not recruiting
NCT05517265 — Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) · active not recruiting
NCT05284591 — Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03911219 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by iOMEDICO AG
Last refreshed: 5 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03911219.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing